JP2022519341A5 - - Google Patents

Info

Publication number
JP2022519341A5
JP2022519341A5 JP2021539922A JP2021539922A JP2022519341A5 JP 2022519341 A5 JP2022519341 A5 JP 2022519341A5 JP 2021539922 A JP2021539922 A JP 2021539922A JP 2021539922 A JP2021539922 A JP 2021539922A JP 2022519341 A5 JP2022519341 A5 JP 2022519341A5
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
antibody fragment
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539922A
Other languages
English (en)
Japanese (ja)
Other versions
JP7606706B2 (ja
JP2022519341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2020/050047 external-priority patent/WO2020144697A1/en
Publication of JP2022519341A publication Critical patent/JP2022519341A/ja
Publication of JP2022519341A5 publication Critical patent/JP2022519341A5/ja
Priority to JP2024213235A priority Critical patent/JP7788118B2/ja
Application granted granted Critical
Publication of JP7606706B2 publication Critical patent/JP7606706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539922A 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体 Active JP7606706B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213235A JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791808P 2019-01-13 2019-01-13
US62/791,808 2019-01-13
PCT/IL2020/050047 WO2020144697A1 (en) 2019-01-13 2020-01-13 Antibodies specific to human nectin-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213235A Division JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Publications (3)

Publication Number Publication Date
JP2022519341A JP2022519341A (ja) 2022-03-23
JP2022519341A5 true JP2022519341A5 (cg-RX-API-DMAC7.html) 2023-01-20
JP7606706B2 JP7606706B2 (ja) 2024-12-26

Family

ID=69701225

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539922A Active JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Country Status (9)

Country Link
US (2) US12545727B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908372A1 (cg-RX-API-DMAC7.html)
JP (2) JP7606706B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210117277A (cg-RX-API-DMAC7.html)
CN (2) CN118878685A (cg-RX-API-DMAC7.html)
AU (1) AU2020207664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3125962A1 (cg-RX-API-DMAC7.html)
IL (1) IL284807B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020144697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243763A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies directed against nectin-2 and their drug conjugates
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
AU2024277235A1 (en) 2023-05-23 2025-12-04 Fondazione per l'Istituto Oncologico di Ricerca Monospecific and bispecific antibodies and antibody-drug conjugates targeting nectin2 (cd112) and psma
WO2024240899A1 (en) 2023-05-23 2024-11-28 Universite De Geneve Dual targeting of psma and nectin2 in prostate cancer
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
KR102997535B1 (ko) 2024-05-08 2026-07-30 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 항체 및 이의 용도
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도
KR20250175021A (ko) 2024-06-05 2025-12-16 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 인간화 항체 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1996037621A2 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
CA2639119A1 (en) 2005-10-07 2007-04-19 Takeda Pharmaceutical Company Limited Agent for preventing/treating cancer
EP2067791A4 (en) 2006-10-06 2009-11-25 Takeda Pharmaceutical PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST CANCER
WO2008126847A1 (ja) 2007-04-11 2008-10-23 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
EP2800196B1 (en) 2011-12-27 2018-09-26 LG Chem, Ltd. Lithium secondary battery and preparation thereof
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
EP3350206A1 (en) 2015-09-14 2018-07-25 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
RU2756275C2 (ru) * 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
WO2017189963A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20190365806A1 (en) * 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
CA3243763A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies directed against nectin-2 and their drug conjugates

Similar Documents

Publication Publication Date Title
JP2021522801A5 (cg-RX-API-DMAC7.html)
US12077583B2 (en) Antibodies specific to human NECTIN4
KR102812377B1 (ko) 인간 폴리오바이러스 수용체(pvr)에 특이적인 항체
CN110511278B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
JP2019511212A5 (cg-RX-API-DMAC7.html)
US20260116971A1 (en) Antibodies specific to human nectin-2
JP2018532383A5 (cg-RX-API-DMAC7.html)
JP2018521008A (ja) 腫瘍形成を処置するための治療用組成物および治療方法
HUE035865T2 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
TW201625270A (zh) 用於治療贅瘤形成的治療組合及方法
JP2021512107A5 (cg-RX-API-DMAC7.html)
CN112292399A (zh) 抗cd27抗体及其用途
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
JP2023517794A (ja) 抗tnfr2抗体及びその使用
US11325976B2 (en) Anti-programmed death-ligand 1 (PD-L1) antibodies and therapeutic uses thereof
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
RU2021118587A (ru) Антитела, специфичные в отношении нектина-2 человека
RU2020133629A (ru) Антитела, специфичные к нектину-4 человека
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
JP2024540320A5 (cg-RX-API-DMAC7.html)
HK40090273A (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
HK40060175A (en) Antibodies specific to human nectin-2
NZ745564B2 (en) Antibodies specific to human poliovirus receptor (pvr)